FDA approves CMV prevention drug, PREVYMIS, for adult stem cell transplant patients
by Press Release from Outbreak News Today on (#37NRT)
The U.S. Food and Drug Administration (FDA) on Thursday approved Merck's PREVYMISa (letermovir) once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). CMV is a common and potentially serious viral ["]
The post FDA approves CMV prevention drug, PREVYMIS, for adult stem cell transplant patients appeared first on Outbreak News Today.